Tempest Therapeutics Receives Nasdaq Non-Compliance Notice for Delayed Annual Meeting, Plans to Regain Compliance by January 27
Summary
Tempest Therapeutics received a Nasdaq non-compliance notice for not holding its annual meeting, but has a meeting scheduled for January 27, 2026, which is expected to resolve the issue.
Key Events
-
Nasdaq Non-Compliance Notice Received
On January 8, 2026, Tempest Therapeutics received a letter from Nasdaq's Listing Qualifications Department indicating non-compliance with Listing Rules 5620(a) and 5810(c)(2)(G).
-
Reason for Non-Compliance
The non-compliance stems from the company's failure to hold an annual meeting of stockholders within twelve months of its fiscal year end of December 31, 2024.
-
Path to Regain Compliance
The company has 45 calendar days (until February 23, 2026) to regain compliance or submit a plan. Tempest Therapeutics has already scheduled its 2025 Annual Meeting for January 27, 2026, and expects to regain compliance upon holding it.
Analysis
Tempest Therapeutics received a notice from Nasdaq regarding its failure to hold an annual meeting within the required timeframe. While such notices are serious and can lead to delisting, the company has already scheduled its 2025 Annual Meeting for January 27, 2026. Upon holding this meeting, Tempest Therapeutics expects to regain compliance with Nasdaq's listing requirements. Investors should monitor the successful execution of the annual meeting to confirm the resolution of this compliance issue.
At the time of this filing, TPST was trading at $2.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.2M. The 52-week trading range was $2.75 to $13.26. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.